GlassScriptPhysician profile
Jacquelyn Adley
NPI 1487990230
$15,632.45
in general payments reported to CMS, 2019-2025
58 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,639 · 2022: $3,707 · 2023: $2,622 · 2024: $3,031 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,137 · Education: $89.56 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,137.30 |
| Education | $89.56 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,190.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,752.80 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Recordati_rare_diseases_inc. | $1,281.06 | 2021-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $1,010.17 | 2021-2025 | |
| Amgen INC. | $755.46 | 2021-2025 | Repatha, Tepezza, Repatha |
| Corcept Therapeutics | $710.04 | 2021-2025 | Korlym |
| Mannkind Corporation | $607.62 | 2021-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $524.44 | 2021-2023 | Farxiga |
| Esperion Therapeutics, INC. | $522.04 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.92 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $448.91 | 2021-2024 | |
| Insulet Corporation | $418.36 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $381.77 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Madrigal Pharmaceuticals | $365.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Antares Pharma, INC. | $348.51 | 2021-2025 | Xyosted, Nocdurna, Tlando |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $321.87 | 2022-2025 | |
| Eusa Pharma (US) LLC | $297.55 | 2022 | |
| Dexcom, INC. | $282.35 | 2021-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $262.90 | 2022-2024 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.15 | 2021-2024 | Cycloset |
| Intuity Medical INC | $191.62 | 2022 | |
| Abbott Laboratories | $184.00 | 2024-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Medtronic, INC. | $170.68 | 2021-2024 | Inpen Smart Insulin Delivery System |
| Amneal Pharmaceuticals LLC | $149.74 | 2021-2025 | Unithroid |
| Ibsa Pharma INC. | $147.57 | 2021-2024 | Tirosint, Licart, Licart |
| Tandem Diabetes Care, INC. | $122.71 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $108.51 | 2021-2025 | |
| Beta Bionics, INC. | $105.73 | 2024 | Ilet Bionic Pancreas |
| Embecta Corp. | $101.61 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Merck Sharp & Dohme LLC | $97.97 | 2021-2023 | Steglujan, Segluromet, Steglatro |
| Clarus Therapeutics INC. | $97.83 | 2021 | |
| Ironwood Pharmaceuticals, INC | $97.06 | 2021-2023 | Linzess |
| Zealand Pharma US, INC. | $79.72 | 2021 | |
| Avvisto Therapeutics, LLC | $60.16 | 2024-2025 | Cycloset |
| Pfizer INC. | $58.59 | 2021 | |
| Sequel Med Tech, LLC | $53.87 | 2025 | Twiist |
| Astellas Pharma US INC | $52.99 | 2024-2025 | Veozah |
| Radius Health, INC. | $50.99 | 2024-2025 | Tymlos |
| Amarin Pharma, INC. | $49.53 | 2021 | |
| Acella Pharmaceuticals, LLC | $46.18 | 2025 | NP Thyroid 60 |
| Nestle Healthcare Nutrition INC. | $40.81 | 2022 | |
| Neurocrine Biosciences, INC. | $40.26 | 2024-2025 | |
| Halozyme INC | $39.67 | 2023 | |
| Ascendis Pharma Endocrinology INC | $37.42 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $26.67 | 2023 | Strensiq |
| Amryt Pharma Holdings LTD | $23.38 | 2022 | |
| Becton, Dickinson and Company | $21.92 | 2022 | |
| Chiesi USA, INC. | $20.38 | 2024 | Myalept |
| Nevro Corp. | $20.35 | 2023 | Senza |
| Janssen Pharmaceuticals, INC | $19.95 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $18.77 | 2024 | |
| Kyowa Kirin, INC. | $15.54 | 2023 | |
| Glaxosmithkline, LLC. | $13.82 | 2025 | Arexvy |
| Almatica Pharma LLC | $13.75 | 2025 | Loreev Xr |
| Azurity Pharmaceuticals, INC. | $13.75 | 2023 | Adthyza |
| Lifescan, INC. | $11.31 | 2021 | |
| Currax Pharmaceuticals LLC | $11.08 | 2021 | |
| Theracosbio, LLC | $5.77 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Adley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.